Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Global Health | 5 | 2021 | 13911 | 0.51 | Why? |
| Reimbursement, Incentive | 1 | 2012 | 70 | 0.47 | Why? |
| Health Services Research | 1 | 2018 | 756 | 0.46 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2017 | 533 | 0.44 | Why? |
| Healthcare Financing | 1 | 2012 | 129 | 0.42 | Why? |
| Ethiopia | 4 | 2019 | 1222 | 0.42 | Why? |
| Community Health Services | 1 | 2019 | 1000 | 0.40 | Why? |
| Health Facilities | 1 | 2018 | 1230 | 0.39 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.33 | Why? |
| Disaster Planning | 1 | 2018 | 1680 | 0.29 | Why? |
| Catastrophic Illness | 1 | 2003 | 41 | 0.27 | Why? |
| Primary Health Care | 2 | 2019 | 4839 | 0.26 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.25 | Why? |
| CD4 Lymphocyte Count | 3 | 2021 | 1517 | 0.23 | Why? |
| Quality of Health Care | 1 | 2012 | 1948 | 0.21 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.20 | Why? |
| Africa, Western | 1 | 2021 | 363 | 0.20 | Why? |
| Developing Countries | 2 | 2012 | 4283 | 0.18 | Why? |
| Health Planning Guidelines | 1 | 2018 | 133 | 0.17 | Why? |
| Maternal-Child Health Services | 1 | 2018 | 124 | 0.16 | Why? |
| HIV Infections | 6 | 2018 | 11620 | 0.15 | Why? |
| Influenza Pandemic, 1918-1919 | 1 | 2020 | 339 | 0.15 | Why? |
| Health Expenditures | 1 | 2003 | 904 | 0.15 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.15 | Why? |
| Intimate Partner Violence | 1 | 2021 | 363 | 0.15 | Why? |
| Democratic Republic of the Congo | 3 | 2021 | 500 | 0.14 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.13 | Why? |
| Cost of Illness | 1 | 2003 | 1903 | 0.12 | Why? |
| Communicable Disease Control | 3 | 2021 | 29620 | 0.12 | Why? |
| Operations Research | 1 | 2011 | 27 | 0.12 | Why? |
| Peripartum Period | 1 | 2011 | 89 | 0.11 | Why? |
| Program Evaluation | 1 | 2019 | 1929 | 0.10 | Why? |
| Guinea | 2 | 2020 | 228 | 0.10 | Why? |
| Adaptive Immunity | 1 | 2020 | 2585 | 0.09 | Why? |
| Child Health | 1 | 2018 | 940 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Guideline Adherence | 1 | 2021 | 2309 | 0.09 | Why? |
| Infectious Disease Transmission, Vertical | 2 | 2018 | 5164 | 0.09 | Why? |
| Health Equity | 1 | 2019 | 1223 | 0.08 | Why? |
| Continuity of Patient Care | 1 | 2017 | 1574 | 0.08 | Why? |
| Humans | 23 | 2021 | 930598 | 0.08 | Why? |
| Hemorrhagic Fever, Ebola | 1 | 2018 | 1475 | 0.08 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.07 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 2984 | 0.07 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.07 | Why? |
| International Cooperation | 1 | 2018 | 3436 | 0.07 | Why? |
| Self Medication | 1 | 2004 | 131 | 0.06 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| Pregnancy | 4 | 2021 | 23879 | 0.06 | Why? |
| Fraud | 1 | 2004 | 116 | 0.06 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.06 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.06 | Why? |
| Medically Underserved Area | 1 | 2003 | 273 | 0.05 | Why? |
| Mali | 1 | 2020 | 181 | 0.05 | Why? |
| Breast Feeding | 1 | 2011 | 1585 | 0.05 | Why? |
| Senegal | 1 | 2020 | 283 | 0.05 | Why? |
| Burkina Faso | 1 | 2020 | 302 | 0.05 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.05 | Why? |
| Pregnancy Complications, Infectious | 2 | 2018 | 11559 | 0.05 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.05 | Why? |
| Epidemics | 1 | 2018 | 6407 | 0.04 | Why? |
| Insurance, Health | 1 | 2003 | 634 | 0.04 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.04 | Why? |
| Phlebography | 1 | 1976 | 65 | 0.04 | Why? |
| Infant | 2 | 2017 | 30274 | 0.04 | Why? |
| Sexual Partners | 1 | 2021 | 612 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Violence | 1 | 2021 | 534 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Malaria | 1 | 2004 | 1097 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| United States | 1 | 2020 | 46150 | 0.03 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.03 | Why? |
| Antimalarials | 1 | 2004 | 2505 | 0.03 | Why? |
| Africa | 1 | 2021 | 2986 | 0.03 | Why? |
| Adult | 7 | 2021 | 244371 | 0.03 | Why? |
| Healthy People Programs | 1 | 2011 | 31 | 0.03 | Why? |
| Zidovudine | 1 | 2011 | 63 | 0.03 | Why? |
| Nevirapine | 1 | 2011 | 57 | 0.03 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.03 | Why? |
| Poverty | 1 | 2003 | 2302 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Child | 2 | 2018 | 70012 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Malawi | 1 | 2011 | 287 | 0.03 | Why? |
| Hand Disinfection | 1 | 2021 | 1671 | 0.03 | Why? |
| Lamivudine | 1 | 2011 | 210 | 0.03 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.02 | Why? |
| Double-Blind Method | 1 | 2021 | 5988 | 0.02 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.02 | Why? |
| HIV Seropositivity | 1 | 2011 | 320 | 0.02 | Why? |
| Sputum | 1 | 1997 | 1720 | 0.02 | Why? |
| Female | 7 | 2021 | 380317 | 0.02 | Why? |
| United Nations | 1 | 2011 | 367 | 0.02 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.02 | Why? |
| Goals | 1 | 2011 | 335 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 1997 | 1164 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2021 | 2844 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| Male | 6 | 2021 | 367725 | 0.02 | Why? |
| Tuberculosis, Pulmonary | 1 | 1997 | 1171 | 0.02 | Why? |
| Africa South of the Sahara | 1 | 2011 | 1335 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2021 | 4545 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2021 | 10017 | 0.02 | Why? |
| Mefloquine | 1 | 2004 | 39 | 0.02 | Why? |
| Drug Labeling | 1 | 2004 | 65 | 0.02 | Why? |
| Sesquiterpenes | 1 | 2004 | 77 | 0.02 | Why? |
| National Health Programs | 1 | 2011 | 807 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2011 | 2324 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2021 | 5837 | 0.02 | Why? |
| Asia, Southeastern | 1 | 2004 | 390 | 0.02 | Why? |
| Health Policy | 1 | 2003 | 6242 | 0.02 | Why? |
| Artemisinins | 1 | 2004 | 238 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Mass Screening | 1 | 2018 | 8005 | 0.01 | Why? |
| Masks | 1 | 2021 | 8528 | 0.01 | Why? |
| Dermoid Cyst | 1 | 1976 | 6 | 0.01 | Why? |
| Mucocele | 1 | 1976 | 6 | 0.01 | Why? |
| Lacrimal Apparatus | 1 | 1976 | 17 | 0.01 | Why? |
| Exophthalmos | 1 | 1976 | 17 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2011 | 7268 | 0.01 | Why? |
| Orbital Neoplasms | 1 | 1976 | 27 | 0.01 | Why? |
| Meningioma | 1 | 1976 | 37 | 0.01 | Why? |
| Eye Neoplasms | 1 | 1976 | 71 | 0.01 | Why? |
| Thrombophlebitis | 1 | 1976 | 94 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.01 | Why? |
| Eye | 1 | 1976 | 374 | 0.01 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.01 | Why? |
| Infant, Newborn | 1 | 2011 | 23105 | 0.01 | Why? |
| Public Health | 1 | 2011 | 16359 | 0.00 | Why? |
| Sensitivity and Specificity | 1 | 1997 | 22971 | 0.00 | Why? |